Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Fludarabine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.78 |
| ▸ | NT5E | P21589 | 6/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.59 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.59 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.59 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.59 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.59 |
| ▸ | LDHA | P00338 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | FBP1 | P09467 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.59 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL28199095 | 0.99 | CA5A (0.77) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL5329821 | 0.97 | CA5A (0.73) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL4744004 | 0.97 | CA5A (0.73) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL1650192 | 0.88 | CA5A (1.00) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL17541855 | 0.88 | CA5A (1.00) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL23884975 | 0.88 | CA5A (1.00) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL899922 | 0.88 | CA5A (1.00) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL21173132 | 0.88 | CA5A (1.00) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL482449 | 0.88 | CA5A (1.00) | CA5ANT5EIMPDH2P2RY1P2RY11 | |
| Fludarabine Phosphate SCHEMBL8401646 | 0.88 | CA5A (1.00) | CA5ANT5EIMPDH2P2RY1P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113597433-A | GPRC5D chimeric antigen receptors and cells expressing these receptors | 詹森生物科技公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-110505877-A | RNA cancer vaccine | MODERNATX INC | 2019-11-26 | — | — | CN | disclosed |
| CN-109414436-A | Treatment of hematological malignancies with 2- (4-chlorophenyl) -N- ((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2, 2-difluoroacetamide | 细胞基因公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109152836-A | Nano immune conjugate and its application based on polymalic acid | 西奈医疗中心 | 2019-01-04 | — | — | CN | disclosed |
| CN-108700590-A | Cell population analysis | 英国质谱公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108602849-A | For by RNA nanotechnologies by the RNA ligand presen-tation allochthons of therapeutic agent specific delivery to cell | 俄亥俄州国家创新基金会 | 2018-09-28 | — | — | CN | disclosed |
| CN-108430456-A | Cancer vaccine | 摩登纳特斯有限公司 | 2018-08-21 | — | — | CN | disclosed |
| CN-107667288-A | Spectral analysis of microorganisms | 英国质谱公司 | 2018-02-06 | — | — | CN | disclosed |
| CN-107530346-A | The solvation form of bruton's tyrosine kinase inhibitor | 药品循环有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107530347-A | The co-crystal thereof of bruton's tyrosine kinase inhibitor | 药品循环有限责任公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107073115-A | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | 细胞基因公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-106999471-A | Cancer diagnosis and treatment | 吉列斯莫钦杜研究所 | 2017-08-01 | — | — | CN | disclosed |
| CN-107002043-A | The survivin specific t-cell receptor of target tumor and non-T cell | 贝勒医学院 | 2017-08-01 | — | — | CN | disclosed |
| CN-106572990-A | Therapeutic combinations comprising estrogen receptor modulators | 豪夫迈·罗氏有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106488767-A | Adjust the method and composition of ERs mutant | 豪夫迈·罗氏有限公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-103596947-A | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders | AMIRA PHARMACEUTICALS INC | 2014-02-19 | — | — | CN | disclosed |
| CN-102612367-A | Prolyl hydroxylase inhibitors | AKEBIA THERAPEUTICS INC | 2012-07-25 | — | — | CN | disclosed |
| CN-102595896-A | Method for improving stability of hypoxia inducible factor-1 alpha | AKEBIA THERAPEUTICS INC | 2012-07-18 | — | — | CN | disclosed |
| CN-102438452-A | Compounds and compositions comprising cdk inhibitors and methods for the treatment of cancer | UNIV GEORGIA STATE RES FOUND | 2012-05-02 | — | — | CN | disclosed |